Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

EURTAC showed that first-line Tarceva nearly doubled the time people with NSCLC with EGFR activating mutations lived without their disease getting worse compared with chemotherapy (median progression-free survival or PFS: 9.7 months compared with 5.2 months). Tarceva significantly reduced the risk of the disease getting worse by 63 percent compared with standard chemotherapy (hazard ratio=0.37, p

Print